MEDICLIN Reports Strong 41.7% Profit Growth in First Nine Months of 2025

MEDICLIN Aktiengesellschaft, a prominent German healthcare provider and member of the Asklepios Group, has reported robust financial performance for the first nine months of 2025, demonstrating significant growth across key metrics. The company, which operates 31 clinics, six care facilities, and nine medical care centers with approximately 8,200 beds and 9,900 employees, achieved consolidated group sales of EUR 586.9 million—a substantial 5.1% increase compared to the same period last year. More impressively, the group operating result surged to EUR 48.9 million, representing a remarkable 41.7% improvement over the previous year's EUR 34.5 million. Overall capacity utilization remained stable at 86.8%, indicating efficient operations across MEDICLIN's extensive healthcare network that provides integrative patient care from initial consultation through surgery, rehabilitation, and outpatient aftercare.

The company's performance was driven by particularly strong results in the post-acute segment, where sales increased by 9.3% to EUR 394.6 million and operating result rose by EUR 9.6 million to EUR 47.6 million. This segment showed improved efficiency with the cost of materials ratio falling by 0.9 percentage points to 19.5%, despite personnel expenses increasing by 9.4% to EUR 205.0 million due to salary adjustments and workforce expansion. The acute segment, while experiencing a 3.2% sales decrease primarily due to the sale of MEDICLIN Herzzentrum Coswig, showed remarkable operational improvement with operating result turning positive at EUR 0.7 million compared to a EUR -3.8 million loss in the previous year. The service segment also contributed positively with sales increasing to EUR 74.8 million and operating result improving by EUR 0.8 million, though the nursing care segment showed some challenges with a slight operating loss.

CFO Tino Fritz expressed confidence in the company's trajectory, confirming that MEDICLIN remains on track to achieve its original annual guidance despite typical seasonal effects in the fourth quarter. The management board maintains its forecast for 2025 financial year with consolidated group sales growth between 2.0% and 5.0% and consolidated group EBIT projected between EUR 53.0 million and EUR 64.0 million. The interim report as of September 30, 2025, is available in both German and English at www.mediclin.de, providing comprehensive details for investors and stakeholders interested in the company's performance and strategic direction. Additional information can be obtained through Investor Relations contact Ender Gulcan, and the original release can be viewed on www.newmediawire.com.